The subcutaneous implantable cardioverter–defibrillator (ICD) was designed to avoid complications related to the transvenous ICD lead by using an entirely extrathoracic placement. Evidence comparing ...

Please provide your email address to receive an email when new articles are posted on . A subcutaneous implantable cardioverter defibrillator was noninferior to a transvenous ICD regarding major ...

In a typical population of patients requiring implantable cardioverter-defibrillator (ICD) therapy without pacing, mostly for the primary prevention of sudden cardiac death, a subcutaneous ICD (S-ICD; ...

Implantable cardioverter–defibrillators (ICDs) prevent sudden death from cardiac causes in selected patients but require the use of transvenous lead systems. To eliminate the need for venous access, ...

Patients with an indication for an implantable cardiac defibrillator for primary prevention of sudden cardiac death and a sharply reduced left ventricular ejection fraction of 35% or less safely ...

The FDA today approved the Subcutaneous Implantable Defibrillator (S-ICD) system from Cameron Health. The device is the first ICD that does not require a lead that connects directly to the heart and ...

Traditionally implantable cardioverter defibrillators (ICDs) have been implanted transvenously by creating a pouch in the subclavicular area and gaining vascular access to the heart. This approach, ...

Cameron Health, Inc. today announced the publication of study results online in the New England Journal of Medicine (NEJM) highlighting the development and potential benefits of the company's S-ICD® ...

Implantable cardioverter-defibrillators (ICDs) reduce mortality in patients with increased risk of sudden cardiac death, but use of these devices has been limited by complications with the ...

Electric shocks delivered by subcutaneous defibrillators are equally effective compared to shocks delivered by conventional transvenous defibrillators, according to a study published in the journal ...

The US FDA study is intended to evaluate the system for treating life-threatening ventricular tachyarrhythmias.

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window BOSTON -- An ...